News & Resources

MEDIA COVERAGE

Press Releases

Articles

PRESENTATIONS

Events

View All

Presentations

Oct 19, 2024 |

Study PRO-101: Experience implementing an ALS community advisory board in early phase drug development

Press Release

Sep 26, 2024 |

ProJenX and Unlearn Announce Partnership to Augment ALS Clinical Trial PRO-101 with Digital Twin Model

Press Release

Aug 27, 2024 |

ProJenX Announces Formation of Clinical Advisory Board

Press Release

Jun 20, 2024 |

ProJenX Announces Receipt of $1M Hoffman ALS Clinical Trial Award from the ALS Association

Press Release

Mar 28, 2024 |

ProJenX Announces Removal of Partial Clinical Hold for Prosetin Program by FDA

Press Release

Feb 14, 2024 |

ProJenX Receives European Authorization for First Study of Prosetin in People Living with ALS

Press Release

Nov 29, 2023 |

ProJenX Receives Health Canada Clinical Trial Application Authorization for First Study of Prosetin in People Living with ALS

Press Release

Nov 2, 2023 |

ProJenX Announces Initial Closing of $15M Series A Financing and Appoints Rick Hartz to Board of Directors

Press Release

Mar 30, 2023 |

ProJenX Announces Formation of Scientific Advisory Board

Events

Nov 16, 2022 |

Join ProJenX at the 2022 International Symposium on ALS/MND

Presentations

Nov 16, 2022 |

Safety and pharmacokinetics of prosetin, a novel, brain penetrant MAP4K inhibitor in development for the treatment of ALS

Media Coverage

Nov 16, 2022 | GEN: Genetic Engineering and Biotechnology News

Stress Test: ProJenX’s Oral Drug Shows Early Promise vs. ALS

Contact Us to Learn More About Our Fight Against ALS